

Introduction

- Mortality from SARS-CoV-2 infection varies according to age
- Immunosuppressed transplant patients shielded as 'clinically extremely vulnerable'
- Mortality in first wave >20%
- Transplant and wait-list patients prioritised for vaccination (tier 4)
- Efficacy of vaccination remains unknown



Registry analysis of SARS-Cov-2 vaccination efficacy in wait-listed and transplant recipients.

- Approvals to link the PHE and Vaccine Registries with the NHSBT transplant and waiting list registries
- Aim to be live for 1st May.
- Similar principle to links established during 1st wave of pandemic


ORIGINAL ARTICLE

AJ

SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: A national cohort study

Rommel Ravanan¹ | Chris J. Callaghan² | Lisa Mumford³ | Ines Ushiro-Lumb⁴ | Douglas Thorburn⁵ | John Casey⁶ | Peter Friend⁷ | Jayan Parameshwar⁸ | Ian Currie⁹ | Lisa Burnapp¹⁰ | Richard Baker¹¹ | Jan Dudley¹² | Gabriel C. Oniscu¹³ | Marius Berman¹⁴ | John Asher¹⁵ | Dan Harvey¹⁶ | Alex Manara¹⁷ | Derek Manas¹¹ | Dale Gardiner¹⁸ | John L. R. Forsythe¹⁹

Registry analysis of SARS-Cov-2 vaccination efficacy in wait-listed and transplant recipients.



Registry analysis of SARS-Cov-2 vaccination efficacy in wait-listed and transplant recipients.

- Compare mortality / hospital admission in vaccinated vs non-vaccinated transplant / waiting list patients.
- Compare transplant population against general population.
- Correlate humoral / cellular responses to the vaccine with level of protection.